‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

medpagetoday.com·May 31, 2026 · 1 g fa

Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy

medicalxpress.com·Jun 1, 2026 · 22 h fa

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis, death

morningstar.com·May 31, 2026 · 1 g fa

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

statnews.com·May 31, 2026 · 1 g fa

For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds

endpoints.news·Jun 1, 2026 · 23 h fa

J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain

independent.co.uk·Jun 1, 2026 · 1 g fa

Prostate cancer breakthrough as drug combo gives patients a powerful new chance

medpagetoday.com·May 31, 2026 · 2 g fa

Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer

economictimes.indiatimes.com·May 31, 2026 · 1 g fa

Johnson & ​Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study

dailymail.com·May 31, 2026 · 1 g fa

Hope for thousands as new drug cuts prostate cancer relapse risk

fiercepharma.com·May 31, 2026 · 1 g fa

ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win